Moderna’s mRNA Flu Shot Under Scrutiny
Is 26.6% efficacy worth a 75.7% side-effect rate? Three authors re-ran the FDA’s own mFLUSIVA data and found two unexplained deaths per hospitalization averted.
What does the data show when Moderna’s mRNA flu vaccine is evaluated using absolute measures of benefit and risk?
Host: Dr. Joseph Varon | Guests: Dr. Peter McCullough, Nicolas Hulscher, and Dr. John Catanzaro
https://imahealth.substack.com/p/modernas-mrna-flu-shot-under-scrutiny?
1 hour
The flu shot is a product that runs on trust. You trust your doctor, your doctor trusts the health authorities, and the authorities tell you to get one every fall. Nobody along that chain shows you what the data says. Your chance of catching influenza in any given year is 2 to 4% at most, and if you are 65, your chance of being hospitalized with it is about one in a thousand. The vaccine on offer has historically prevented fewer than half of the cases it targets, because manufacturers have to guess the strains months ahead. And yet, half the country still decides to roll up their sleeves.
Even the flu death toll you hear every winter is softer than it sounds. Here is how it gets counted, according to Dr. Peter McCullough: if a person tests positive for influenza at any point during flu season, and if they die of anything during that time, then they are officially tallied as a flu death. He cites estimates that only about 15% of those people died of the flu itself; most died of a bacterial pneumonia that set in afterward. That inflated number is what the television ads lean on, and what hospitals cite when they tell staff to take the shot or lose their privileges. Dr. McCullough has taken 40 flu shots for exactly that reason.
So when the FDA licensed an mRNA version of the flu shot in August, it got our attention. Flu vaccination had all of these problems before anyone touched the technology. Now it carries the same mRNA platform as the COVID-19 injections, and that platform has already shown everyone how many ways a novel product can go wrong. IMA urged caution the week it was approved, and Dr. Joseph Varon had warned against rushing mRNA flu platforms more than a year before that.
Now the three authors of a new paper in the Journal of Independent Medicine have re-run the FDA’s own trial data as plain head counts: how many people had to get the shot for one of them to be helped, and how many were harmed along the way. All three join Dr. Varon to walk through what they found.